Skip to content
White_Message

02/12/2024 – We are currently experiencing issues with our digital ‘contact us’ forms. We appreciate your patience and understanding as we work to resolve this. For urgent matters, please contact us via 0333 103 9499. Alternatively, please email us at generalenquries@sciensus.com with your Full Name, DOB, Postcode and the details of your query.

The impact of real-world data in gaining access to the European orphan drugs market. 

Mathieu Loiseau

By Mathieu Loiseau

Director of Rare Clinical Services

Gain key insights: RWD’s role in successful drug launches

Europe presents a significant opportunity for international biotech’s developing and commercialising rare and orphan medicines. 

With the EMA’s increasing focus on Real-World Data in its regulatory processes, there are several ways in which applying it can help speed up access to the European market.

This essential guide covers:

  • What is Real-World Data and how it is used in the pharmaceutical industry
  • How RWD can help to speed up access to European markets
  • The importance of RWD in regulatory and HTA submissions
  • RWD as a strategic tool for pricing and reimbursement negotiations
  • The advantages of RWD over controlled clinical trial data
  • The EMA’s recognition of RWD

Download this exclusive guide to discover how Real-World Data can improve your chance of success in this complex market.